EZH2: An analysis of a potential new tumor marker in high-risk localization of cutaneous squamous cell carcinomas.

Front Oncol · 2024 · PMC11933827 · PMID 40135141

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The EZH2-score-I showed a trend of increasing with AJCC stage, but the discrepancy in the score was not statistically significant: AJCC-I M = 6.13; SD = 2.56; 95% CI 5.02–7.24; AJCC-II M = 6.47; SD = 2.77; 95% CI 5.14–7.81; AJCC-III M = 6.16; SD = 2.71; 95% CI 5.39–6.92; AJCC-IV M = 7.79; SD = 3.35; 95% CI 6.52–9.07; Kruskal-Wallis-Test, p = 0.118; Likelihood ratio, p = 0.569.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.